Cell death in response to antimetabolites directed at thymidylate synthase

Cancer Chemotherapy and Pharmacology

Volumn 61, Issue 2, 2008, Pages 189-201

  Barbour, Karen W ^a   Berger, Franklin G ^a  

^a UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMETABOLITE; CASPASE; CASPASE 3; CASPASE 8; CYTOKINE; FAS ANTIGEN; FAS LIGAND; FLOXURIDINE; FLUOROURACIL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; RALTITREXED; THYMIDYLATE SYNTHASE; THYMIDYLATE SYNTHASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; ARTICLE; CELL DEATH; COLON TUMOR; CONTROLLED STUDY; DRUG MECHANISM; DRUG RESPONSE; ENZYME ACTIVITY; ENZYME DEGRADATION; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSMISSION ELECTRON MICROSCOPY; TUMOR CELL; WESTERN BLOTTING;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BLOTTING, WESTERN; CASPASES; CELL DEATH; CELL LINE, TUMOR; COLONIC NEOPLASMS; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ENZYME INHIBITORS; HUMANS; INDICATORS AND REAGENTS; MICROSCOPY, ELECTRON, TRANSMISSION; NECROSIS; NF-KAPPA B; THYMIDINE; THYMIDYLATE SYNTHASE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 36348988441     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-007-0461-4     Document Type: Article

References (56)

1. Danenberg PV (1977) Thymidylate synthetase-a target enzyme in cancer chemotherapy. Biochim Biophys Acta 473:73-92
2. Carreras CW, Santi DV (1995) The catalytic mechanism and structure of thymidylate synthase. Annu Rev Biochem 64:721-762
3. Krokan HE, Drablos F, Slupphaug G (2002) Uracil in DNA-occurrence, consequences and repair. Oncogene 21:8935-8948
4. Santi DV, McHenry CS, Raines RT, Ivanetich KM (1987) Kinetics and thermodynamics of the interaction of 5-fluoro-2′-deoxyuridylate with thymidylate synthase. Biochemistry 26:8606-8613
5. Takemura Y, Jackman AL (1997) Folate-based thymidylate synthase inhibitors in cancer chemotherapy. Anticancer Drugs 8:3-16
6. Bertino JR (1997) Chemotherapy of colorectal cancer: history and new themes. Semin Oncol 24:S18-13-S18-17
7. Bertino JR (1997) Biomodulation of 5-fluorouracil with antifolates. Semin Oncol 24:S18-52-S18-56
8. Jenh CH, Geyer PK, Baskin F, Johnson LF (1985) Thymidylate synthase gene amplification in fluorodeoxyuridine-resistant mouse cell lines. Mol Pharmacol 28:80-85
9. Berger SH, Jenh CH, Johnson LF, Berger FG (1985) Thymidylate synthase overproduction and gene amplification in fluorodeoxyuridine-resistant human cells. Mol Pharmacol 28:461-467
10. Barbour KW, Berger SH, Berger FG (1990) Single amino acid substitution defines a naturally occurring genetic variant of human thymidylate synthase. Mol Pharmacol 37:515-518
11. Houghton PJ, Rahman A, Will CL, Dolnick BJ, Houghton JA (1992) Mutation(s) of the thymidylate synthase gene of human adenocarcinoma cells causes a thymidylate synthase-negative phenotype that can be attenuated by exogenous folates. Cancer Res 52:558-565
12. Berger SH, Barbour KW, Berger FG (1988) A naturally occurring variation in thymidylate synthase structure is associated with a reduced response to 5-fluoro-2′-deoxyuridine in a human colon tumor cell line. Mol Pharmacol 34:480-484
13. Kitchens ME, Forsthoefel AM, Barbour KW, Spencer HT, Berger FG (1999) Mechanisms of acquired resistance to thymidylate synthase inhibitors: the role of enzyme stability. Mol Pharmacol 56:1063-1070
14. Longley DB, Harkin DP, Johnston PG (2003) 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3:330-338
15. Tillman DM, Petak I, Houghton JA (1999) A Fas-dependent component in 5-fluorouracil/leucovorin-induced cytotoxicity in colon carcinoma cells. Clin Cancer Res 5:425-430
16. Petak I, Tillman DM, Harwood FG, Mihalik R, Houghton JA (2000) Fas-dependent and -independent mechanisms of cell death following DNA damage in human colon carcinoma cells. Cancer Res 60:2643-2650
17. Longley DB, Allen WL, McDermott U, Wilson TR, Latif T, Boyer J, Lynch M, Johnston PG (2004) The roles of thymidylate synthase and p53 in regulating Fas-mediated apoptosis in response to antimetabolites. Clin Cancer Res 10:3562-3571
18. Harwood FG, Kasibhatla S, Petak I, Vernes R, Green DR, Houghton JA (2000) Regulation of FasL by NF-kappaB and AP-1 in Fas-dependent thymineless death of human colon carcinoma cells. J Biol Chem 275:10023-10029
19. Wang S, El-Deiry WS (2004) Inducible silencing of KILLER/DR5 in vivo promotes bioluminescent colon tumor xenograft growth and confers resistance to chemotherapeutic agent 5-fluorouracil. Cancer Res 64:6666-6672
20. Millar CB, Guy J, Sansom OJ, Selfridge J, MacDougall E, Hendrich B, Keightley PD, Bishop SM, Clarke AR, Bird A (2002) Enhanced CpG mutability and tumorigenesis in MBD4-deficient mice. Science 297:403-405
21. Sansom OJ, Zabkiewicz J, Bishop SM, Guy J, Bird A, Clarke AR (2003) MBD4 deficiency reduces the apoptotic response to DNA-damaging agents in the murine small intestine. Oncogene 22:7130-7136
22. Cortellino S, Turner D, Masciullo V, Schepis F, Albino D, Daniel R, Skalka AM, Meropol NJ, Alberti C, Larue L, Bellacosa A (2003) The base excision repair enzyme MED1 mediates DNA damage response to antitumor drugs and is associated with mismatch repair system integrity. Proc Natl Acad Sci USA 100:15071-15076
23. Geller JI, Szekely-Szucs K, Petak I, Doyle B, Houghton JA (2004) P21Cip1 is a critical mediator of the cytotoxic action of thymidylate synthase inhibitors in colorectal carcinoma cells. Cancer Res 64:6296-6303
24. Fiers W, Beyaert R, Declercq W, Vandenabeele P (1999) More than one way to die: apoptosis, necrosis and reactive oxygen damage. Oncogene 18:7719-7730
25. Jaattela M, Tschopp J (2003) Caspase-independent cell death in T lymphocytes. Nat Immunol 4:416-423
26. Jaattela M (2004) Multiple cell death pathways as regulators of tumour initiation and progression. Oncogene 23:2746-2756
27. Broker LE, Kruyt FA, Giaccone G (2005) Cell death independent of caspases: a review. Clin Cancer Res 11:3155-3162
28. Vercammen D, Brouckaert G, Denecker G, Van de Craen M, Declercq W, Fiers W, Vandenabeele P (1998) Dual signaling of the Fas receptor: initiation of both apoptotic and necrotic cell death pathways. J Exp Med 188:919-930
29. Okada M, Adachi S, Imai T, Watanabe K, Toyokuni SY, Ueno M, Zervos AS, Kroemer G, Nakahata T (2004) A novel mechanism for imatinib mesylate-induced cell death of BCR-ABL-positive human leukemic cells: caspase-independent, necrosis-like programmed cell death mediated by serine protease activity. Blood 103:2299-2307
30. Zong WX, Ditsworth D, Bauer DE, Wang ZQ, Thompson CB (2004) Alkylating DNA damage stimulates a regulated form of necrotic cell death. Genes Dev 18:1272-1282
31. Suarez Y, Gonzalez L, Cuadrado A, Berciano M, Lafarga M, Munoz A (2003) Kahalalide F, a new marine-derived compound, induces oncosis in human prostate and breast cancer cells. Mol Cancer Ther 2:863-872
32. Kakutani T, Ebara Y, Kanja K, Hidaka M, Matsumoto Y, Nagano A, Wataya Y (1998) Different modes of cell death induced by 5-fluoro-2′-deoxyuridine in two clones of the mouse mammary tumor FM3A cell line. Biochem Biophys Res Commun 247:773-779
33. Troyano A, Fernandez C, Sancho P, de Blas E, Aller P (2001) Effect of glutathione depletion on antitumor drug toxicity (apoptosis and necrosis) in U-937 human promonocytic cells. The role of intracellular oxidation. J Biol Chem 276:47107-47115
34. Gonzalez VM, Fuertes MA, Alonso C, Perez JM (2001) Is cisplatin-induced cell death always produced by apoptosis? Mol Pharmacol 59:657-663
35. Aggarwal BB (2004) Nuclear factor-kappaB: the enemy within. Cancer Cell 6:203-208
36. Karin M (2006) Nuclear factor-kappaB in cancer development and progression. Nature 441:431-436
37. Whiteside ST, Epinat JC, Rice NR, Israel A (1997) I kappa B epsilon, a novel member of the I kappa B family, controls RelA and cRel NF-kappa B activity. Embo J 16:1413-1426
38. Barbour KW, Hoganson DK, Berger SH, Berger FG (1992) A naturally occurring tyrosine to histidine replacement at residue 33 of human thymidylate synthase confers resistance to 5-fluoro-2′-deoxyuridine in mammalian and bacterial cells. Mol Pharmacol 42:242-248
39. Pahl HL (1999) Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 18:6853-6866
40. Cai Z, Korner M, Tarantino N, Chouaib S (1997) IkappaB alpha overexpression in human breast carcinoma MCF7 cells inhibits nuclear factor-kappaB activation but not tumor necrosis factor-alpha-induced apoptosis. J Biol Chem 272:96-101
41. Bentires-Alj M, Hellin AC, Ameyar M, Chouaib S, Merville MP, Bours V (1999) Stable inhibition of nuclear factor kappaB in cancer cells does not increase sensitivity to cytotoxic drugs. Cancer Res 59:811-815
42. Eichhorst ST, Muerkoster S, Weigand MA, Krammer PH (2001) The chemotherapeutic drug 5-fluorouracil induces apoptosis in mouse thymocytes in vivo via activation of the CD95(APO-1/Fas) system. Cancer Res 61:243-248
43. Zhang XD, Wu JJ, Gillespie S, Borrow J, Hersey P (2006) Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin. Clin Cancer Res 12:1355-1364
44. Leist M, Single B, Castoldi AF, Kuhnle S, Nicotera P (1997) Intracellular adenosine triphosphate (ATP) concentration: a switch in the decision between apoptosis and necrosis. J Exp Med 185:1481-1486
45. Nicotera P, Melino G (2004) Regulation of the apoptosis-necrosis switch. Oncogene 23:2757-2765
46. Hwang PM, Bunz F, Yu J, Rago C, Chan TA, Murphy MP, Kelso GF, Smith RA, Kinzler KW, Vogelstein B (2001) Ferredoxin reductase affects p53-dependent, 5-fluorouracil-induced apoptosis in colorectal cancer cells. Nat Med 7:1111-1117
47. Liu G, Chen X (2002) The ferredoxin reductase gene is regulated by the p53 family and sensitizes cells to oxidative stress-induced apoptosis. Oncogene 21:7195-7204
48. Choi W, Gerner EW, Ramdas L, Dupart J, Carew J, Proctor L, Huang P, Zhang W, Hamilton SR (2005) Combination of 5-fluorouracil and N1,N11- diethylnorspermine markedly activates spermidine/spermine N1-acetyltransferase expression, depletes polyamines, and synergistically induces apoptosis in colon carcinoma cells. J Biol Chem 280:3295-3304
49. Maxwell PJ, Longley DB, Latif T, Boyer J, Allen W, Lynch M, McDermott U, Harkin DP, Allegra CJ, Johnston PG (2003) Identification of 5-fluorouracil- inducible target genes using cDNA microarray profiling. Cancer Res 63:4602-4606
50. Voboril R, Hochwald SN, Li J, Brank A, Weberova J, Wessels F, Moldawer LL, Camp ER, MacKay SL (2004) Inhibition of NF-kappa B augments sensitivity to 5-fluorouracil/folinic acid in colon cancer. J Surg Res 120:178-188
51. Li J, Minnich DJ, Camp ER, Brank A, Mackay SL, Hochwald SN (2006) Enhanced sensitivity to chemotherapy in esophageal cancer through inhibition of NF-kappaB. J Surg Res 132:112-120
52. Camp ER, Li J, Minnich DJ, Brank A, Moldawer LL, MacKay SL, Hochwald SN (2004) Inducible nuclear factor-kappaB activation contributes to chemotherapy resistance in gastric cancer. J Am Coll Surg 199:249-258
53. Konishi T, Sasaki S, Watanabe T, Kitayama J, Nagawa H (2006) Overexpression of hRFI inhibits 5-fluorouracil-induced apoptosis in colorectal cancer cells via activation of NF-kappaB and upregulation of BCL-2 and BCL-XL. Oncogene 25:3160-3169
54. Kasperczyk H, La Ferla-Bruhl K, Westhoff MA, Behrend L, Zwacka RM, Debatin KM, Fulda S (2005) Betulinic acid as new activator of NF-kappaB: molecular mechanisms and implications for cancer therapy. Oncogene 24:6945-6956
55. Poppelmann B, Klimmek K, Strozyk E, Voss R, Schwarz T, Kulms D (2005) NF{kappa}B-dependent down-regulation of tumor necrosis factor receptor-associated proteins contributes to interleukin-1-mediated enhancement of ultraviolet B-induced apoptosis. J Biol Chem 280:15635-15643
56. Ravi R, Bedi GC, Engstrom LW, Zeng Q, Mookerjee B, Gelinas C, Fuchs EJ, Bedi A (2001) Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-kappaB. Nat Cell Biol 3:409-416